BST-2 restricts SARS Coronavirus and is antagonized by SARS-CoV ORF7a
Authors
Advisor
Date
Embargo until
Language
Book title
Publisher
Peer Reviewed
Type
Research Area
Jurisdiction
Other Titles
See at
Abstract
Severe Acute Respiratory Syndrome (SARS) emerged in November 2002 as a case of atypical pneumonia in the Guandong Province in China. The causative agent SARS was identified as a novel coronavirus, severe acute respiratory syndrome coronavirus (SARS-CoV). Bone marrow stromal antigen 2 (or BST-2; also known as CD317 or tetherin) was initially identified as a pre-B-cell growth promoter but was identified as a viral antagonist. BST-2 inhibits the release of the retrovirus human immunodeficiency virus type 1 (HIV-1) virions by directly tethering budding virions from the host cell and further work has shown that BST-2 restricts the release of many other viruses, including alphaviruses, arenaviruses, herpesviruses, paramyxoviruses, and other retroviruses. BST-2 has recently been shown to restrict a human coronavirus, hCoV-229E. Many of these viruses, including hCoV-229E, are not only restricted by BST-2, but encode BST-2 antagonists to overcome BST-2 restriction. Given, the previous studies on BST-2, we aimed to determine if BST-2 has the ability to restrict SARS-CoV and if SARS-CoV encodes any BST-2 antagonists. Through an in vitro screen we identified four potential BST-2 antagonists, PLPro, nsp1, ORF6, and ORF7a, encoded by SARS-CoV. Due to the gap in knowledge of the function of ORF7a, we focused our study on ORF7a. We found that BST-2 does restrict SARS-CoV, but the loss of ORF7a leads to a much greater restriction, which confirmed the role of ORF7a as a BST-2 antagonist. We further characterized the mechanism of BST-2 antagonism by ORF7a and found that ORF7a acts by a novel mechanism, localizes with and directly binds BST-2. ORF7a interferes with glycosylation of BST-2, although it is unclear whether ORF7a antagonizes BST-2 by blocking glycosylation or by binding to conserved patches of BST-2 and blocking glycosylation is just a side effect. We used a mouse model to evaluate the role of BST-2 in vivo and found that wild type and BST-2 -/- mice showed similar virus titer, weight loss, and lung pathology. While the BST-2 -/- mice did not show enhanced disease, there are several factors that may conceal a phenotype.